Effect of Osimertinib in Ethnic Chinese With EGFR and T790M Mutated NSCLC
- Sponsor
- AstraZeneca
- Study ID
- NCT03133234
- Status
- Completed
Conditions
- T790M Positive NSCLC Patients
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- osimertinib — DRUGOral dose of 80mg once daily
Study Details
To assess the effectiveness and safety of osimertinib treatment in a real world setting.
Key Dates
- First listed
- Apr 28, 2017
- Start date
- May 23, 2017
- Status verified
- Nov 2018
- Primary completion
- Sep 13, 2017
- Completion
- Sep 13, 2017
Study Design
- Enrollment
- 47 participants (actual)
Arms
- Arm: EGFR T790M PatientsPatients with locally advanced/metastatic EGFR T790M positive NSCLC progressed on previous EGFR TKI
Primary Outcome Measure
ORR [ Time Frame: Followed up with 6 months after last patient in ]